BioMedNewsBreaks

TuesdayMar 16, 2021 12:45 pm

BioMedNewsBreaks – Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Announces Continued Manufacturing Progress

Imagin Medical (CSE: IME) (OTCQB: IMEXF), a surgical imaging company focused on establishing a new standard of care in visualizing cancer during minimally invasive procedures, today announced continued progress towards commercial-stage manufacturing capability with Lighthouse Imaging. Prior to selection of Lighthouse as its contract manufacturer for the i/Blue Imaging System(TM) in October 2020, Imagin received multiple fully functional feasibility units from its original design partner, Optel Inc. Lighthouse’s development program has since focused on further refining the design to support Imagin’s submissions to the U.S. Food and Drug Administration, as well as to ensure final device performance, compliance with all…

Continue Reading

TuesdayMar 16, 2021 12:19 pm

BioMedNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Participation Schedule for Upcoming March Investor Conferences

VistaGen (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders, today announced that its Chief Executive Officer, Shawn Singh, will participate in two investor conferences in March. For the Maxim Group and M-Vest’s Inaugural Emerging Growth Virtual Conference taking place on March 17-19, 2021, Singh will deliver a corporate presentation and participate in a fireside chat, scheduled to begin at 1 p.m. ET on Friday, March 19. In addition, Singh will deliver a corporate presentation at the Benzinga Biotech…

Continue Reading

TuesdayMar 16, 2021 9:46 am

BioMedNewsBreaks – Predictive Oncology (NASDAQ: POAI) Releases FY 2020 Financial Results, Business Highlights

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has reported business highlights and  financial results for the year ended Dec. 31, 2020. Highlights discussed in the report include the company’s reinforced balance sheet with net debt and equity offerings for estimated net proceeds of $12,952,689; completion of an asset purchase agreement to acquire Soluble Therapeutics and its exclusive technology, as well as BioDtech Inc.; completion of the asset purchase of Quantitative Medicine (“QM”); and the signing of a contract with a pharmaceutical company for protein expression and solubility studies.…

Continue Reading

FridayMar 12, 2021 1:09 pm

BioMedNewsBreaks – Imagin Medical Inc.’s (CSE: IME) (OTCQB: IMEXF) Solution Solves Cystoscopy Challenges

Imagin Medical (CSE: IME) (OTCQB: IMEXF), a surgical imaging company, has developed a product that deals with the challenges associated with both blue light and white light cystoscopies. Clinical data support the value of blue light cystoscopy in detecting bladder cancer. Despite this fact, “the technology is used in less than 10% of such procedures because of the high cost of equipment.” Secondly, white light cystoscopy is ineffective in detecting all tumors. This poses a challenge as surgeons have to switch “back and forth between white light and blue light images to locate and resect tumors. And that’s where Imagin…

Continue Reading

FridayMar 12, 2021 11:52 am

BioMedNewsBreaks – United Medical Equipment Business Solutions Network Inc. Poised to Play Key Role in Fast Tracking Economic Revival

United Medical Equipment (“UME,” “UMEBSNI”), a supplier of both antigen and antibody COVID-19 test kits, is poised to capitalize on the increasing need for rapid testing. This follows the findings of a recent study published by the University of Colorado Boulder and Harvard University, which shows that frequent rapid testing could curb COVID-19 within weeks. “Factors such as turnaround time and frequency are key in limiting the spread of the virus, making rapid tests one of the key tools for managing the virus outbreak,” reads an article on United Medical’s positioning. “As such,” it continues, “the rapid tests are increasingly…

Continue Reading

FridayMar 12, 2021 11:26 am

BioMedNewsBreaks – Brain Scientific Inc.’s (BRSF) Next-Gen NeuroCap EEG Headset Featured in Syndicate Broadcast

Brain Scientific (OTCQB: BRSF) is featured in a broadcast released from NetworkNewsAudio (“NNA”), a solution that delivers additional visibility, recognition and brand awareness in the investment community via distribution to thousands of syndication points. The new audio press release focuses on the 510(k) clearance the U.S. Food and Drug Administration (“FDA”) has given to Brain Scientific’s next-generation NeuroCap(TM) device. The NeuroCap is an advanced clectroencephalogram (“EEG”) electrode array that obtains rapid EEGs in a variety of settings, from routine clinical and research settings to point of contact, where recording of STAT EEGs is needed. BRSF’s proprietary NeuroCap is a disposable, pre-gelled EEG headset…

Continue Reading

FridayMar 12, 2021 10:39 am

BioMedNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Featured in Latest Episode of Bell2Bell Podcast

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) was featured in the The Bell2Bell Podcast, a part of InvestorBrandNetwork’s (“IBN”) sustained effort to provide specialized content distribution via widespread syndication channels. XPhyto Therapeutics’ CEO and Director, Hugh Rogers, joined the latest episode to discuss the company’s recent receipt of its ISO certification and its rapid point-of-care COVID-19 PCR diagnostic test. “We expect to be in the market very soon, within 30 days, pending European approval right now,” Rogers said. “Testing is highly relevant and will be for many years to come. The virus is endemic. It appears that it will…

Continue Reading

ThursdayMar 11, 2021 11:27 am

BioMedNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Leaders to Present at Upcoming Virtual Investor Summit

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing including obstructive sleep apnea (“OSA”) has announced that CEO Kirk Huntsman, CFO Brad Amman and investor relations officer Ed Loew are scheduled to present at the Q1 Virtual Investor Summit. Vivos Therapeutics’ presentation is scheduled for 1:30 p.m. ET on March 23, 2021. The presentation will include an overview of the company and other relevant information for potential investors. Formerly MicroCap Conference, the Investor Summit has gained a reputation as an exclusive, independent conference that connects small cap and…

Continue Reading

ThursdayMar 11, 2021 10:23 am

BioMedNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Preclinical Data Demonstrating Differentiated Mechanism of Action of PH10 from Benzodiazepines

VistaGen (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (“CNS”) disorders, today announced promising preclinical data for its PH10 drug candidate. The data demonstrate that the potential mechanism of action of PH10, VistaGen’s Phase 2 investigational pherine nasal spray with potential as a rapid-onset, stand-alone treatment for major depressive disorder (“MDD”), does not involve direct activation of GABA-A receptors. This is in distinct contrast to the mechanism of action of benzodiazepines, which act as direct positive modulators of GABA-A receptors. Instead, PH10 is designed to engage receptors in nasal chemosensory neurons,…

Continue Reading

WednesdayMar 10, 2021 12:00 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Leverages ‘Absolute Powerhouse Compound’ as IND Status Paves Way for Clinical Trials

CNS Pharmaceuticals (NASDAQ: CNSP) CEO John Climaco, in a recent podcast, showed his excitement at news that the U.S. Food and Drug Administration (“FDA”) had granted Berubicin investigational new drug (“IND”) status. The IND designation clears the way for the company to start human clinical trials and to ship the experimental drug across state lines to clinical investigators. “This is the biggest news we’ve announced since our IPO back in November 2019,” Climaco said of the significant milestone. “Based on that IND approval, we expect, in the next 90 to 120 days, we will go from zero active clinical trials…

Continue Reading